Jean Jacques Bienaime - 02 Nov 2022 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role: Chief Executive Officer, Director
Signature: /s/ Eric Fleekop, Attorney-in-Fact
Issuer symbol: BMRN
Transactions as of: 02 Nov 2022
Net transactions value: -$147,355
Form type: 4
Filing time: 06 Dec 2022, 20:09:42 UTC
Previous filing: 01 Nov 2022
Next filing: 15 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BMRN	Common Stock	Small acquisition under Rule 16a-6	$8,612	+100	+0.03%	$86.12	322,924	02 Nov 2022	Direct
transaction	BMRN	Common Stock	Sale	$48,970	-471	-0.15%	$103.97	322,453	02 Dec 2022	Direct
transaction	BMRN	Common Stock	Sale	$62,383	-600	-0.19%	$103.97	321,853	02 Dec 2022	Direct
transaction	BMRN	Common Stock	Sale	$27,035	-260	-0.08%	$103.98	321,593	02 Dec 2022	Direct
transaction	BMRN	Common Stock	Sale	$10,400	-100	-0.03%	$104.00	321,493	02 Dec 2022	Direct	F1
transaction	BMRN	Common Stock	Sale	$7,180	-69	-0.02%	$104.06	321,424	02 Dec 2022	Direct	F1
holding	BMRN	Common Stock						247,533	02 Nov 2022	Shares held by Jean-Jacques Bienaime Family Trust

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 100 shares, with the reporting person's purchase of shares at a price of $86.1178 on November 2, 2022. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.

Content

The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 100 shares, with the reporting person's purchase of shares at a price of $86.1178 on November 2, 2022. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.